UPDATE: Stifel Starts 908 Devices Inc. (MASS) at Buy

Stifel analyst Daniel Arias initiates coverage on 908 Devices Inc. (NASDAQ: MASS) with a Buy rating and a price target of $65.00.

The analyst comments "We are initiating coverage of MASS with a Buy rating and a $65 price target. We see 908 Devices as an emerging life sciences player that is positioned squarely in the center of two of the most attractive portions of the life sciences market (biologic drug development and applied science testing) with a differentiated set of offerings within a proven technology class. As such, we believe the growth opportunity is significant today, and even more significant as the company’s platforms evolve. While commercialization is admittedly in the earlier stages for key portions of the portfolio, our confidence in both 908’s development trajectory and outlook for the company’s markets underpins a favorable stock view over the next 12 months."

For an analyst ratings summary and ratings history on 908 Devices Inc. click here. For more ratings news on 908 Devices Inc. click here.

Shares of 908 Devices Inc. closed at $56.63 yesterday.

You May Also Be Interested In

• Zoetis Inc. (ZTS) PT Lowered to $80 at Stifel as Key Franchise Price Realization Decelerates
• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Elanco Animal Health (ELAN) Reiterated at Buy by Stifel as Rebate Activity Accelerates